"I would like Europe to become a centre of excellence and a focus for pharmaceutical research once again", stated EU Research Commissioner Philippe Busquin today at the annual assembly of the European pharmaceutical industry (EFPIA) in Bruges. "We need to nurture our research-based industries by reinforcing science and technology in Europe. Europe needs to invest more and in a better, more consistent way: it has to cut red tape and be bold." From 1999 to 2002 the Commission invested around € 1 billion in health-related research. In the next four years, within the new EU research framework programme, at least € 2 billion will be spent in this area, with a particular priority on genomics and biotechnology for health. But this is not enough. In recent years, the competitiveness of EU pharmaceutical industry has decreased. The fact is that the US, with a bigger market for drugs, in particular those based on advances in bio-medicines, has overtaken the EU in total research investment. "The EU has been late in grasping the potential of biotechnology for the development of new drugs," says Commissioner Busquin. "But Europe is catching up: new biotech companies are created every year in the EU. Professional technology transfer and investments in collaborative biotechnology research programmes are on the rise. Our latest Research Programme will foster the competitiveness of the European pharmaceutical industry. But EU funding will only have sufficient leverage if pharmaceutical companies and Member States join us in networking research efforts at EU level."
Commissioner Busquin also refers to the conclusions of the recent Commission Communication on "Biotechnology and Life Sciences": "The Commission and Member States need to work more closely together to develop coherent policies for making the most of biotechnology and life sciences. This will benefit public health and the competitiveness of the European pharmaceutical industry."
"Of course we cannot expect the pharmaceutical industry to invest as much in research as in the US, if the value of the EU market remains at only about half of that of the US, particularly if it does not seem to encourage the introduction of innovative drugs" adds Commissioner Busquin. "Despite this, the EU is only slightly behind the US in terms of biotech patenting activity and in terms of scientific publications we are as good as the US. Indeed, our goal is to attract more investment into EU biotech and pharmaceutical research, whether from EU or US industry, and to make the EU research and innovation system more effective in terms of innovative output".
fabio Fabbi | Europäische Kommission
Chip-based optical sensor detects cancer biomarker in urine
06.12.2019 | The Optical Society
Scientist identify new marker for insecticide resistance in malaria mosquitoes
06.12.2019 | Liverpool School of Tropical Medicine
University of Texas and MIT researchers create virtual UAVs that can predict vehicle health, enable autonomous decision-making
In the not too distant future, we can expect to see our skies filled with unmanned aerial vehicles (UAVs) delivering packages, maybe even people, from location...
With ultracold chemistry, researchers get a first look at exactly what happens during a chemical reaction
The coldest chemical reaction in the known universe took place in what appears to be a chaotic mess of lasers. The appearance deceives: Deep within that...
Abnormal scarring is a serious threat resulting in non-healing chronic wounds or fibrosis. Scars form when fibroblasts, a type of cell of connective tissue, reach wounded skin and deposit plugs of extracellular matrix. Until today, the question about the exact anatomical origin of these fibroblasts has not been answered. In order to find potential ways of influencing the scarring process, the team of Dr. Yuval Rinkevich, Group Leader for Regenerative Biology at the Institute of Lung Biology and Disease at Helmholtz Zentrum München, aimed to finally find an answer. As it was already known that all scars derive from a fibroblast lineage expressing the Engrailed-1 gene - a lineage not only present in skin, but also in fascia - the researchers intentionally tried to understand whether or not fascia might be the origin of fibroblasts.
Fibroblasts kit - ready to heal wounds
Research from a leading international expert on the health of the Great Lakes suggests that the growing intensity and scale of pollution from plastics poses serious risks to human health and will continue to have profound consequences on the ecosystem.
In an article published this month in the Journal of Waste Resources and Recycling, Gail Krantzberg, a professor in the Booth School of Engineering Practice...
03.12.2019 | Event News
15.11.2019 | Event News
15.11.2019 | Event News
06.12.2019 | Earth Sciences
06.12.2019 | Life Sciences
06.12.2019 | Information Technology